3/21/2024

Argatroban Injection

Products Affected - Description

- Argatroban intravenous injection, Fresenius Kabi, 100 mg/mL, 2.5 mL vial, 1 count, NDC 63323-0526-03 - discontinued

Reason for the Shortage

- Eugia has argatroban available.
- Fresenius Kabi has argatroban available. The 100 mg/mL 2.5 mL vials have been discontinued.
- Hikma has argatroban available.
- Viatris did not provide a reason for the shortage.
- Novartis discontinued argatroban.
- Par has argatroban available.
- Pfizer has argatroban available.
- Sagent has argatroban available.
- Sandoz discontinued argatroban 1 mg/mL 50 mL vials in April 2019. Sandoz discontinued argatroban 1 mg/mL 125 mL vials in April 2020.
- Teva is not marketing argatroban.

Available Products

- Argatroban intravenous injection, Eugia US, 1 mg/mL, 50 mL vial, 1 count, NDC 55150-0241-01
- Argatroban intravenous injection, Eugia US, 1 mg/mL, 50 mL vial, 10 count, NDC 55150-0241-10
- Argatroban intravenous injection, Fresenius Kabi, 1 mg/mL, 50 mL vial, 10 count, NDC 65219-0429-50
- Argatroban intravenous injection, Hikma, 1 mg/mL, 50 mL vial, 1 count, NDC 00143-9559-01
- Argatroban intravenous injection, Hikma, 100 mg/mL, 2.5 mL vial, 1 count, NDC 00143-9674-01
- Argatroban intravenous injection, Mylan Institutional (Viatris), 100 mg/mL, 2.5 mL vial, 1 count, NDC 67457-0212-02
- Argatroban intravenous injection, Par Pharmaceuticals, 100 mg/mL, 2.5 mL vial, 1 count, NDC 42023-0182-01
- Argatroban intravenous injection, Pfizer, 100 mg/mL, 2.5 mL vial, 1 count, NDC 00409-1140-01
- Argatroban intravenous injection, Sagent, 1 mg/mL, 50 mL vial, 1 count, NDC 25021-0414-50

Estimated Resupply Dates

- All marketed presentations are available.

Updated

Updated March 21, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 20, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.